EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits

EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits

EGFR mutation in non-small cell lung cancer (NSCLC) offers a potential therapeutic target for tyrosine kinase inhibitor (TKI) therapy. The majority of these cases, however eventually develop therapy resistance, mainly by acquiring EGFR T790M mutation. Recently, third-generation TKIs have been introd...

Full description

Bibliographic Details
Main Authors: Eszter Bencze, Krisztina Bogos, Andrea Kohánka, László Báthory-Fülöp, Veronika Sárosi, Erzsébet Csernák, Nóra Bittner, Zsombor Melegh, Erika Tóth
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Pathology and Oncology Research
Subjects:
liquid biopsy
NSCLC
ctDNA
EGFR T790M mutation
AmoyDx super-ARMS EGFR mutation detection kit
cobas EGFR test v2
Online Access:https://www.por-journal.com/articles/10.3389/pore.2022.1610607/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2022.1610607/full

Similar Items